Correction: The association between sulfonylurea use and all-cause and cardiovascular mortality: A meta-analysis with trial sequential analysis of randomized clinical trials, (PLoS Med, (2016), 13(4), 10.1371/journal.pmed.1001992);The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials

PLoS Medicine

Volumn 13, Issue 4, 2016, Pages

  Varvaki Rados, Dimitris ^a   Catani Pinto, Lana ^a   Reck Remonti, Luciana ^a   Bauermann Leitão, Cristiane ^a   Gross, Jorge Luiz ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; METFORMIN; ROSIGLITAZONE; SULFONYLUREA; SULFONYLUREA DERIVATIVE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DYSLIPIDEMIA; GENETIC HETEROGENEITY; HEART INFARCTION; HUMAN; HYPERTENSION; META ANALYSIS; OUTCOME ASSESSMENT; QUALITY CONTROL; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; MIDDLE AGED; MORTALITY; ODDS RATIO; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84964769831     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/JOURNAL.PMED.1002091     Document Type: Erratum

References (93)

1. Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ, (2013) Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia56: 973–984. doi: 10.1007/s00125-013-2856-623494446
2. (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet352: 837–853. 9742976
3. Klarenbach S, Cameron C, Singh S, Ur E, (2011) Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. CMAJ183: E1213–E1220. doi: 10.1503/cmaj.11017821969406
4. Meinert CL, Knatterud GL, Prout TE, Klimt CR, (1970) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes19 (Suppl): 789–830. 4926376
5. Genuth S, (2015) Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it’s time to move on!Diabetes Care38: 170–175. doi: 10.2337/dc14-056525538314
6. Abrahamson MJ, (2015) Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well!Diabetes Care38: 166–169. doi: 10.2337/dc14-194525538313
7. Nissen SE, (2012) Cardiovascular effects of diabetes drugs: emerging from the dark ages. Ann Intern Med157: 671–672. doi: 10.7326/0003-4819-157-9-201211060-0001623128866
8. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, et al. (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK General Practice Research Database. BMJ339: b4731. doi: 10.1136/bmj.b473119959591
9. Kontopantelis E, Springate DA, Reeves D, Ashcroft DM, Rutter M, et al. (2015) Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study. Diabetologia58: 505–518. doi: 10.1007/s00125-014-3473-825512005
10. Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC, (2014) Ambulatory treatment of type 2 diabetes in the U.S., 1997–2012. Diabetes Care37: 985–992. doi: 10.2337/dc13-209724198301
11. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, et al. (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med373: 232–242. doi: 10.1056/NEJMoa150135226052984
12. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, et al. (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med369: 1317–1326. doi: 10.1056/NEJMoa130768423992601
13. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, et al. (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med369: 1327–1335. doi: 10.1056/NEJMoa130588923992602
14. Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, et al. (2014) Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA311: 2288–2296. doi: 10.1001/jama.2014.431224915260
15. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, et al. (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J32: 1900–1908. doi: 10.1093/eurheartj/ehr07721471135
16. Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, et al. (2012) Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med157: 601–610. doi: 10.7326/0003-4819-157-9-201211060-0000323128859
17. Sedgwick P, (2013) Prospective cohort studies: advantages and disadvantages. BMJ: 347: f6726.
18. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM, (2007) A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care30: 389–394. 17259518
19. Hemmingsen B, Schroll JB, Lund SS, Wetterslev J, Gluud C, et al. (2013) Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev4: CD009008. doi: 10.1002/14651858.CD009008.pub223633364
20. Monami M, Genovese S, Mannucci E, (2013) Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab15: 938–953. doi: 10.1111/dom.1211623594109
21. Phung OJ, Schwartzman E, Allen RW, Engel SS, Rajpathak SN, (2013) Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med30: 1160–1171. doi: 10.1111/dme.1223223663156
22. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA, (2008) Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care31: 1672–1678. doi: 10.2337/dc08-016718458139
23. Bolland MJ, Grey A, Gamble GD, Reid IR, (2014) The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol2: 364–365.
24. Wetterslev J, Thorlund K, Brok J, Gluud C, (2008) Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol61: 64–75. 18083463
25. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, et al. (2011) User manual for Trial Sequential Analysis (TSA). Copenhagen: Copenhagen Trial Unit, Centre for Clinical Intervention Research. 115 p.
26. Higgins JPT, Green S, (2011) Cochrane handbook for systematic reviews of interventions. London: Cochrane Collaboration.
27. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ339: b2535. doi: 10.1136/bmj.b253519622551
28. Bu S, Xing XY, Wang N, Zhao WH, Yang WY, (2004) [Evaluation of the efficacy and safety of once daily injection of glargine combined with glipizide GITS in the treatment of type 2 diabetes mellitus]. Chin J Evid Based Med4: 464–467.
29. Li MK, Liu Q, Yu ZZ, Cui SM, Shi P, et al. (1999) [Observation of the effect of combination of glipizide and insulin for type2 diabetic patients with secondary failure to oral sulfonylureas]. J Clin Int Med15: 38.
30. Onuchin SG, Elsukova OS, Solov’ev OV, Onuchina EL, (2010) [Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus]. Ter Arkh82: 34–41.
31. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, et al. (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ343: d5928. doi: 10.1136/bmj.d592822008217
32. Guyatt GH, Oxman AD, Kunz R, Jaeschke R, Helfand M, et al. (2008) Incorporating considerations of resources use into grading recommendations. BMJ336: 1170–1173. doi: 10.1136/bmj.39504.506319.8018497416
33. Phung OJ, Scholle JM, Talwar M, Coleman CI, (2010) Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA303: 1410–1418. doi: 10.1001/jama.2010.40520388897
34. Gross JL, Kramer CK, Leitao CB, Hawkins N, Viana LV, et al. (2011) Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med154: 672–679. doi: 10.7326/0003-4819-154-10-201105170-0000721576535
35. Diamond GA, Bax L, Kaul S, (2007) Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med147: 578–581. 17679700
36. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A, (2007) Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med26: 53–77. 16596572
37. Sweeting MJ, Sutton AJ, Lambert PC, (2004) What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med23: 1351–1375. 15116347
38. Rucker G, Schwarzer G, Carpenter JR, Schumacher M, (2008) Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol8: 79. doi: 10.1186/1471-2288-8-7919036172
39. Abbatecola AM, Rizzo MR, Barbieri M, Grella R, Arciello A, et al. (2006) Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology67: 235–240. 16864814
40. Ahren B, Johnson SL, Stewart M, Cirkel DT, Yang F, et al. (2014) HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care37: 2141–2148. doi: 10.2337/dc14-002424898304
41. Alvarsson M, Berntorp K, Fernqvist-Forbes E, Lager I, Steen L, et al. (2010) Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: a 6-year follow-up study. Rev Diabet Stud7: 225–232. doi: 10.1900/RDS.2010.7.22521409314
42. Arjona Ferreira JC, Corry D, Mogensen CE, Sloan L, Xu L, et al. (2013) Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis61: 579–587. doi: 10.1053/j.ajkd.2012.11.04323352379
43. Arjona Ferreira JC, Marre M, Barzilai N, Guo H, Golm GT, et al. (2013) Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care36: 1067–1073. doi: 10.2337/dc12-136523248197
44. Birkeland KI, Rishaug U, Hanssen KF, Vaaler S, (1996) NIDDM: a rapid progressive disease. Results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment. Diabetologia39: 1629–1633. 8960854
45. Campbell IW, Menzis DG, Chalmers J, McBain AM, Brown IRF, (1994) One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete Metab20: 394–400. 7843470
46. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, et al. (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet382: 941–950. doi: 10.1016/S0140-6736(13)60683-223850055
47. Clauson P, Karlander S, Steen L, Efendic S, (1996) Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up. Diabet Med13: 471–477. 8737030
48. Del Prato S, Camisasca R, Wilson C, Fleck P, (2014) Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab16: 1239–1246. doi: 10.1111/dom.1237725132212
49. Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, et al. (2009) Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab11: 157–166. doi: 10.1111/j.1463-1326.2008.00994.x19125777
50. Filozof C, Gautier JF, (2010) A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med27: 318–326. doi: 10.1111/j.1464-5491.2010.02938.x20536495
51. Foley JE, Sreenan S, (2009) Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm Metab Res41: 905–909. doi: 10.1055/s-0029-123404219705345
52. Gallwitz B, Guzman J, Dotta F, Guerci B, Simó R, et al. (2012) Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet. 379: 2270–2278. doi: 10.1016/S0140-6736(12)60479-622683137
53. Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, et al. (2012) 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet380: 475–483. doi: 10.1016/S0140-6736(12)60691-622748821
54. Garber A, Henry RR, Ratner R, Hale P, Chang CT, et al. (2011) Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabet Obes Metab13: 348–356.
55. Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA, (2005) PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care28: 2093–2099. 16123472
56. Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, et al. (2010) Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation121: 1176–1187. doi: 10.1161/CIRCULATIONAHA.109.88100320194881
57. Giles TD, Elkayam U, Bhattacharya M, Perez A, Miller AB, (2010) Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. Congest Heart Fail16: 111–117. doi: 10.1111/j.1751-7133.2010.00154.x20557330
58. Göke B, Gallwitz B, Eriksson JG, Hellqvist A, Gause-Nilsson I, (2013) Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract67: 307–316. 23638466
59. Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M, (2008) Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes116: 6–13. 18095238
60. Hanefeld M, Patwardhan R, Jones NP, (2007) A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutr Metab Cardiovasc Dis17: 13–23. 17174222
61. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, et al. (2007) Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med357: 28–38. 17551159
62. Hong J, Zhang Y, Lai S, Lv A, Su Q, et al. (2013) Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care36: 1304–1311. doi: 10.2337/dc12-071923230096
63. Jain R, Osei K, Kupfer S, Perez AT, Zhang J, et al. (2006) Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy26: 1388–1395. 16999648
64. Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, et al. (1998) Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab83: 1515–1522. 9589648
65. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med355: 2427–2443. 17145742
66. Kaku K, Rasmussen MF, Nishida T, Seino Y, (2011) Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes. J Diabetes Investig2: 441–447. doi: 10.1111/j.2040-1124.2011.00128.x24843528
67. Lundershausen R, Orban S, Pissarek D, Panzram G, (1987) [Long-term effect of combination glibenclamide-insulin treatment in the secondary failure of sulfonylurea therapy—results of a one-year double blind study]. Wien Klin Wochenschr99: 603–608. 3118579
68. Madsbad S, Kilhovd B, Lager I, Mustajoki P, Dejgaard A, (2001) Comparison between repaglinide and glipizide in type 2 diabetes mellitus: a 1-year multicentre study. Diabet Med18: 395–401. 11472451
69. Marbury T, Huang WC, Strange P, Lebovitz H, (1999) Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract43: 155–166. 10369424
70. Matthews DR, Dejager S, Ahren B, Fonseca V, Ferrannini E, et al. (2010) Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab12: 780–789. doi: 10.1111/j.1463-1326.2010.01233.x20649630
71. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, et al. (2006) Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA296: 2572–2581. 17101640
72. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Koide H, (2006) Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. Diabetes Metab Res Rev22: 385–389. 16506273
73. Nauck MA, Del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, et al. (2011) Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care34: 2015–2022. doi: 10.2337/dc11-060621816980
74. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP, (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab9: 194–205. 17300595
75. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, et al. (2008) Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA299: 1561–1573. doi: 10.1001/jama.299.13.156118378631
76. Perriello G, Pampanelli S, Brunetti P, di Pietro C, Mariz S, (2007) Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes. Diab Vasc Dis Res4: 226–230. 17907113
77. Petrica L, Petrica M, Vlad A, Dragos Jianu C, Gluhovschi G, et al. (2009) Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wien Klin Wochenschr121: 765–775. doi: 10.1007/s00508-009-1279-320047115
78. Petrica L, Vlad A, Petrica M, Jianu CD, Gluhovschi G, et al. (2011) Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Res Clin Pract94: 22–32. doi: 10.1016/j.diabres.2011.05.03221726916
79. Quatraro A, Consoli G, Ceriello A, Giugliano D, (1986) Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up. Diabete Metab12: 315–318. 3545931
80. Ridderstrale M, Andersen KR, Zeller C, Kim G, Woerle HJ, et al. (2014) Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol2: 691–700. doi: 10.1016/S2213-8587(14)70120-224948511
81. Ristic S, Collober-Maugeais C, Cressier F, Tang P, Pecher E, (2007) Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. Diabetes Obes Metab9: 506–511. 17587393
82. Rosenstock J, Wilson C, Fleck P, (2013) Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab15: 906–914. doi: 10.1111/dom.1210223531118
83. Tolman KG, Freston JW, Kupfer S, Perez A, (2009) Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf32: 787–800.
84. Vahatalo M, Ronnemaa T, Viikari J, (2007) Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice. Scand J Prim Health Care25: 147–153. 17846932
85. Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, et al. (2004) Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ170: 477–480. 14970094
86. Gerstein HC, Miller ME, Byington RP, Goff DC, JrBigger JT, et al. (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med358: 2545–2559. doi: 10.1056/NEJMoa080274318539917
87. US Food and Drug Administration (2008) Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring (Maryland): US Food and Drug Administration.
88. Schernthaner G, Duran-Garcia S, Hanefeld M, Langslet G, Niskanen L, et al. (2015) Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes Obes Metab17: 630–638. doi: 10.1111/dom.1246125761977
89. Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, et al. (2015) Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol3: 43–51. doi: 10.1016/S2213-8587(14)70213-X25466239
90. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet385: 2067–2076. doi: 10.1016/S0140-6736(14)62225-X25765696
91. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, et al. (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med373: 2127–2128.
92. Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, et al. (2013) Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res10: 289–301. doi: 10.1177/147916411247510223449634
93. Nathan DM, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, et al. (2013) Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care36: 2254–2261. doi: 10.2337/dc13-035623690531